Dyne updates DYNE-101 trial timeline, reports strong 12-month data, and receives FDA Breakthrough Therapy status for treating ...

I am upgrading Dyne Therapeutics stock to a 'Buy' rating due to promising late-stage DM1 and DMD drug candidates and ...

US biotech Dyne Therapeutics (Nasdaq: DYN) has revised its regulatory approach for DYNE-101, a treatment in development for ...

The research firm highlighted several factors that may have led to the consideration of visual hand opening time (vHOT) as an endpoint for accelerated approval of DYNE-101. While CASI (a measure ...

Dyne Testing, an Intertronics brand, presents the Sigma 702 Force Tensiometer from Biolin Scientific, a standalone instrument for precise surface tension and interfacial tension measurement. The Sigma ...

Importantly, treatment with DYNE-251 resulted in meaningful improvements in Stride Velocity 95th Centile (SV95C), a digital objective outcome measure of ambulatory performance in a patient’s ...

Preliminary data from both phase 1/2 findings showed that patients given such drugs achieved some measurement of improvement. For instance, when looking at those who received DYNE-101 for DM1 ...

RBC Capital has initiated coverage of Dyne Therapeutics (NASDAQ:DYN) and Avidity Biosciences (NASDAQ:RNA) with outperform ...